Aurinia Pharmaceuticals Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for AUPH, updated each market day.
AUPH AI Sentiment
AI sees no strong directional signal for Aurinia Pharmaceuticals Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Sector
Exchange
Market Cap
$2,122,216,824
Cap Tier
Employees
128
Headquarters
EDMONTON, A0
Listed Since
Oct. 21, 2009
Website
AUPH Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AUPH Volatility
Aurinia Pharmaceuticals Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
